Our platform technology is poised to transform major segments of the $127 billion per year injectable biological therapeutics market.
Of this overall market, our technology is immediately and directly applicable to:
We continue to explore opportunities and collaborate with partners in other therapeutic areas, such as chronic cardiovascular indications and immuno-oncology (for targeted presentation of tumor antigens to antigen presentation cells/dendritic cells in vivo), as well as for the local and/or intracellular delivery of nucleic acid therapeutics (e.g., siRNA, mRNA, antisense) to target cells.
These market opportunities range from orphan and rare indications to those with 'blockbuster' potential, and we are strategically approaching these indications in order to reach patients who will clearly benefit from oral and targeted versions of such biopharmaceutical products and to drive our programs to rapid clinical validation.
Copyright © APPLIED MOLECULAR TRANSPORT, LLC 2016. All rights reserved.